StockData
Innoviva, Inc. logo

Innoviva, Inc. (INVA) stock

INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.30−0.19 (-1.03%)

Close on Nov 17, 2026Market cap $1.32BP/E 9.3Yield –

Innoviva price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Innoviva's price to sales ratio was 3.1× on Nov 11, 2026, against 4.2× a year earlier. Over the last 5 years it ranged from 2.0× to 4.2×, with a median of 3.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.1×−0.7
2025Dec 31, 20253.8×+0.8
2024Dec 31, 20243.1×−0.5
2023Dec 29, 20233.6×+1.1
2022Dec 30, 20222.5×−0.7
2021Dec 31, 20213.2×−0.7
2020Dec 31, 20203.9×−1.5
2019Dec 31, 20195.4×−2.6
2018Dec 31, 20188.0×−1.6
2017Dec 29, 20179.6×−1.6
2016Dec 30, 201611.3×−20.3
2015Dec 31, 201531.6×−428.0
2014Jan 31, 2014459.6×+14.6
2013Dec 31, 2013444.9×+428.9
2012Dec 31, 201216.1×−49.7
2011Dec 30, 201165.8×+0.9
2010Dec 31, 201064.8×–

More Innoviva figures

See a number that looks wrong?